Novltex, a newly developed class of synthetic antibiotics, effectively kills multidrug-resistant bacteria, showing promise against antimicrobial resistance.
Novltex delivers strong and rapid action against some of the most dangerous multidrug-resistant bacteria, offering a promising new tool in the ongoing battle against global antimicrobial resistance (1✔ ✔Trusted Source
Novltex: A New Class of Antibiotics with Potent Activity against Multidrug-Resistant Bacterial Pathogens-Design, Synthesis, and Biological Evaluation
Go to source
).
Scientists from the University of Liverpool, led by Dr. Ishwar Singh, developed Novltex—a groundbreaking class of antibiotics, through international collaboration. The development represents a major advancement in addressing antimicrobial resistance, a crisis responsible for approximately five million deaths each year and recognized by the World Health Organization as one of the top ten global health threats.
Fighting Resistance in High-Risk Pathogens
The World Health Organization has listed several critical “priority pathogens” that urgently require new treatment options, such as methicillin-resistant Staphylococcus aureus and Enterococcus faecium. Novltex has demonstrated strong, quick-acting efficacy against both of these bacteria.
What makes Novltex especially valuable is its unique mechanism of action. Instead of functioning like traditional antibiotics, it attacks lipid II, a crucial element in bacterial cell wall formation that does not mutate. This significantly reduces the likelihood of resistance developing, tackling one of modern medicine’s toughest challenges.
From Soil Bacteria to Lab-Engineered Antibiotics
The discovery builds upon earlier work by Dr. Singh’s team, who had previously engineered simplified synthetic versions of teixobactin, a molecule produced by soil bacteria that kill competing microbes. By creating a specialized library of synthetic teixobactins, the team fine-tuned important properties to improve both the effectiveness and safety of the compounds, while also making them practical for large-scale production.
Using this foundation, Novltex was developed as a modular, synthetic antibiotic platform inspired by both teixobactin and clovibactin. Avoiding costly ingredients, the platform can be tailored to produce multiple variants for further enhancement. Its ability to attack lipid II, a non-mutating bacterial component, makes Novltex highly potent, long-lasting, and manufacturable, positioning it as one of the most promising antibiotic candidates in recent decades.
Proven Power Against Priority Superbugs
The findings, published in the Journal of Medicinal Chemistry by the American Chemical Society, outline several critical attributes of Novltex:
- Effectiveness against top-priority superbugs like methicillin-resistant Staphylococcus aureus and Enterococcus faecium.
- Resilience against resistance due to its focus on an unchanging bacterial target.
- Modular chemical design enabling the creation of optimized variants.
- Highly potent, operating at very low doses and outperforming multiple existing antibiotics including vancomycin, daptomycin, linezolid, levofloxacin, and cefotaxime.
- Safe for human cell models, with production processes up to 30 times more efficient than natural alternatives.
Path Toward Clinical Use
Novltex represents a critical advancement in addressing antimicrobial resistance. Its scalable design, targeting of a structure that does not change, and its high effectiveness against resistant strains show real potential in the fight against superbugs. According to Dr. Singh, international collaboration was key to this progress, as the issue of antimicrobial resistance spans across borders.
The next phase of work will involve testing Novltex in animal infection models to verify its safety and effectiveness in living systems. Researchers also plan to study how the compounds behave within the body and collaborate with global and industrial partners to prepare for human clinical trials.
This pioneering work is backed by Innovate UK, the Department of Health and Social Care, and the Rosetrees Trust. It aligns with the goals of the Therapeutics Innovation frontier, an initiative by the University of Liverpool to lead in transforming the drug discovery process. The initiative leverages collaborations between academia, industry, and global health organizations to tackle major health challenges.
Reference:
- Novltex: A New Class of Antibiotics with Potent Activity against Multidrug-Resistant Bacterial Pathogens─Design, Synthesis, and Biological Evaluation – (https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01193)
Source-Antibiotic